PLN-10195-ONC-101: A Phase 1a/1b Multicenter, Open-label Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of PLN-101095 as Monotherapy and in Combination With Pembrolizumab in Adult Participants With Advanced or Metastatic Solid Tumors Who Have Disease Progression While on an Immune Checkpoint Inhibitor (FORTIFY)

Objective

Clinical Trial Details

Clinical Trial Categories

  • Cancer
  • Colorectal Cancer
  • Lung Cancer
  • Renal/Urinary Tract Cancer
  • Gynecologic Cancer
Contact
Gynecology Research Coordinators at 605-322-7536
or gynresearch@avera.org

Location

  • Avera Cancer Institute — Sioux Falls
    1000 E 23rd St
    Suite 340
    Sioux Falls, SD 57105
    Main: 605-322-3000